{"id":45743,"date":"2025-11-04T20:52:13","date_gmt":"2025-11-04T12:52:13","guid":{"rendered":"https:\/\/flcube.com\/?p=45743"},"modified":"2025-11-04T20:52:14","modified_gmt":"2025-11-04T12:52:14","slug":"ascentage-pharma-unveils-promising-results-for-olverembatinib-and-lisaftoclax-at-the-67th-ash-annual-meeting","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=45743","title":{"rendered":"Ascentage Pharma Unveils Promising Results for Olverembatinib and Lisaftoclax at the 67th ASH Annual Meeting"},"content":{"rendered":"\n<p>China\u2011based <strong>Ascentage Pharma (<a href=\"https:\/\/www.google.com\/finance\/quote\/6855:HKG\">HKG: 6855<\/a>)<\/strong> showcased data from its two flagship pipelines\u2014<strong>olverembatinib<\/strong> (HQP1351), a first\u2011in\u2011China third\u2011generation BCR\u2011ABL inhibitor, and <strong>lisaftoclax<\/strong> (APG\u20112575), an orally available BCL\u20112 antagonist\u2014at the <strong>American Society of Hematology (ASH)<\/strong> 2025 conference.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-olverembatinib\">Olverembatinib<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>POLARIS\u20111, Global Phase\u202f3<\/strong><\/li>\n\n\n\n<li><strong>Population:<\/strong> 53 newly diagnosed (ND) Philadelphia chromosome\u2011positive (Ph\u207a) acute lymphoblastic leukemia (ALL) patients who were eligible for low\u2011intensity chemotherapy.<\/li>\n\n\n\n<li><strong>Efficacy:<\/strong> 94.3\u202f% (50\/53) achieved <strong>complete remission (CR)<\/strong> or <strong>CR with incomplete hematologic recovery (CRi)<\/strong> by induction end\u2011point.<\/li>\n\n\n\n<li><strong>Minimal Residual Disease (MRD):<\/strong> Best MRD\u2011negative rate\u202f=\u202f66.0\u202f%; MRD\u2011negative\u202fCR rate\u202f=\u202f64.2\u202f%.<\/li>\n\n\n\n<li><strong>Safety:<\/strong> The combination was well tolerated with no new safety signals.<\/li>\n\n\n\n<li><strong>4\u2011Year Follow\u2011Up, Randomized Phase\u202fII<\/strong><\/li>\n\n\n\n<li><strong>Population:<\/strong> Tyrosine\u2011kinase\u2011inhibitor (TKI)\u2011resistant chronic\u2011phase chronic myeloid leukemia (CML\u2011CP).<\/li>\n\n\n\n<li><strong>Outcome:<\/strong> Sustained durable responses and favorable safety mirror results of the Phase\u202fII second\u2011line study in non\u2011T315I\u2011mutant CML\u2011CP patients.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-lisaftoclax\">Lisaftoclax<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Phase\u202fII, R\/R CLL\/SLL<\/strong><\/li>\n\n\n\n<li><strong>Population:<\/strong> Relapsed\/refractory (R\/R) chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) heavily pre\u2011treated with BTK inhibitors.<\/li>\n\n\n\n<li><strong>Oral BCL\u20112 Inhibition:<\/strong> Independent review committee (IRC) confirmed an overall response rate (ORR) of <strong>62.5\u202f%<\/strong>.<\/li>\n\n\n\n<li><strong>Durability:<\/strong> Median progression\u2011free survival (mPFS) reached <strong>23.9\u202fmonths<\/strong>\u2014the longest PFS reported for a single\u2011agent BCL\u20112 inhibitor in BTK\u2011refractory disease.<\/li>\n\n\n\n<li><strong>Safety:<\/strong> Toxicity was manageable, with the most common adverse events being cytopenias and infusion\u2011related reactions, neither requiring dose escalation.<\/li>\n\n\n\n<li><strong>Lisaftoclax + Azacitidine (AZA) \u2013 Myeloid Resilience<\/strong><\/li>\n\n\n\n<li><strong>Population:<\/strong> Newly diagnosed (ND) or venetoclax\u2011pre\u2011treated myeloid malignancies.<\/li>\n\n\n\n<li><strong>Finding:<\/strong> The combination effectively overcomes venetoclax resistance, showing early clinical promise and encouraging further dosing exploration.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-implications\">Market Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Hematology Leadership:<\/strong> Ascentage\u2019s ability to deliver the first Phase\u202f3 data for a third\u2011generation BCR\u2011ABL inhibitor and compelling single\u2011agent BCL\u20112 data positions it as a formidable competitor to established Western biotech players.<\/li>\n\n\n\n<li><strong>Expansion Opportunities:<\/strong> Olverembatinib\u2019s low\u2011intensity chemo backbone offers a tolerable regimen for younger patients, while lisaftoclax\u2019s oral delivery meets the unmet need for convenient outpatient therapy in CLL\/SLL.<\/li>\n\n\n\n<li><strong>Strategic Partnerships:<\/strong> The favorable safety profiles and durable responses support Ascentage\u2019s pursuit of global co\u2011development agreements, especially in the U.S. and Europe where BCR\u2011ABL and BCL\u20112 inhibitors are in high demand.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2025110400034_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025110400034_c.\"><\/object><a id=\"wp-block-file--media-4b380c10-527c-4d37-a748-fb709976c2dd\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2025110400034_c.pdf\">2025110400034_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2025110400034_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-4b380c10-527c-4d37-a748-fb709976c2dd\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China\u2011based Ascentage Pharma (HKG: 6855) showcased data from its two flagship pipelines\u2014olverembatinib (HQP1351), a first\u2011in\u2011China&#8230;<\/p>\n","protected":false},"author":1,"featured_media":45745,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[106,200,17,985],"class_list":["post-45743","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-academic-conference","tag-ascentage-pharma","tag-clinical-trial-results","tag-hkg-6855"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Ascentage Pharma Unveils Promising Results for Olverembatinib and Lisaftoclax at the 67th ASH Annual Meeting - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2011based Ascentage Pharma (HKG: 6855) showcased data from its two flagship pipelines\u2014olverembatinib (HQP1351), a first\u2011in\u2011China third\u2011generation BCR\u2011ABL inhibitor, and lisaftoclax (APG\u20112575), an orally available BCL\u20112 antagonist\u2014at the American Society of Hematology (ASH) 2025 conference.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=45743\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ascentage Pharma Unveils Promising Results for Olverembatinib and Lisaftoclax at the 67th ASH Annual Meeting\" \/>\n<meta property=\"og:description\" content=\"China\u2011based Ascentage Pharma (HKG: 6855) showcased data from its two flagship pipelines\u2014olverembatinib (HQP1351), a first\u2011in\u2011China third\u2011generation BCR\u2011ABL inhibitor, and lisaftoclax (APG\u20112575), an orally available BCL\u20112 antagonist\u2014at the American Society of Hematology (ASH) 2025 conference.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=45743\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-04T12:52:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-04T12:52:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0403.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45743#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45743\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Ascentage Pharma Unveils Promising Results for Olverembatinib and Lisaftoclax at the 67th ASH Annual Meeting\",\"datePublished\":\"2025-11-04T12:52:13+00:00\",\"dateModified\":\"2025-11-04T12:52:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45743\"},\"wordCount\":382,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45743#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0403.webp\",\"keywords\":[\"Academic conference\",\"Ascentage Pharma\",\"Clinical trial results\",\"HKG: 6855\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45743#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45743\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=45743\",\"name\":\"Ascentage Pharma Unveils Promising Results for Olverembatinib and Lisaftoclax at the 67th ASH Annual Meeting - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45743#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45743#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0403.webp\",\"datePublished\":\"2025-11-04T12:52:13+00:00\",\"dateModified\":\"2025-11-04T12:52:14+00:00\",\"description\":\"China\u2011based Ascentage Pharma (HKG: 6855) showcased data from its two flagship pipelines\u2014olverembatinib (HQP1351), a first\u2011in\u2011China third\u2011generation BCR\u2011ABL inhibitor, and lisaftoclax (APG\u20112575), an orally available BCL\u20112 antagonist\u2014at the American Society of Hematology (ASH) 2025 conference.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45743#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45743\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45743#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0403.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0403.webp\",\"width\":1080,\"height\":608,\"caption\":\"Ascentage Pharma Unveils Promising Results for Olverembatinib and Lisaftoclax at the 67th ASH Annual Meeting\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45743#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ascentage Pharma Unveils Promising Results for Olverembatinib and Lisaftoclax at the 67th ASH Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ascentage Pharma Unveils Promising Results for Olverembatinib and Lisaftoclax at the 67th ASH Annual Meeting - Insight, China&#039;s Pharmaceutical Industry","description":"China\u2011based Ascentage Pharma (HKG: 6855) showcased data from its two flagship pipelines\u2014olverembatinib (HQP1351), a first\u2011in\u2011China third\u2011generation BCR\u2011ABL inhibitor, and lisaftoclax (APG\u20112575), an orally available BCL\u20112 antagonist\u2014at the American Society of Hematology (ASH) 2025 conference.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=45743","og_locale":"en_US","og_type":"article","og_title":"Ascentage Pharma Unveils Promising Results for Olverembatinib and Lisaftoclax at the 67th ASH Annual Meeting","og_description":"China\u2011based Ascentage Pharma (HKG: 6855) showcased data from its two flagship pipelines\u2014olverembatinib (HQP1351), a first\u2011in\u2011China third\u2011generation BCR\u2011ABL inhibitor, and lisaftoclax (APG\u20112575), an orally available BCL\u20112 antagonist\u2014at the American Society of Hematology (ASH) 2025 conference.","og_url":"https:\/\/flcube.com\/?p=45743","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-04T12:52:13+00:00","article_modified_time":"2025-11-04T12:52:14+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0403.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=45743#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=45743"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Ascentage Pharma Unveils Promising Results for Olverembatinib and Lisaftoclax at the 67th ASH Annual Meeting","datePublished":"2025-11-04T12:52:13+00:00","dateModified":"2025-11-04T12:52:14+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=45743"},"wordCount":382,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=45743#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0403.webp","keywords":["Academic conference","Ascentage Pharma","Clinical trial results","HKG: 6855"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=45743#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=45743","url":"https:\/\/flcube.com\/?p=45743","name":"Ascentage Pharma Unveils Promising Results for Olverembatinib and Lisaftoclax at the 67th ASH Annual Meeting - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=45743#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=45743#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0403.webp","datePublished":"2025-11-04T12:52:13+00:00","dateModified":"2025-11-04T12:52:14+00:00","description":"China\u2011based Ascentage Pharma (HKG: 6855) showcased data from its two flagship pipelines\u2014olverembatinib (HQP1351), a first\u2011in\u2011China third\u2011generation BCR\u2011ABL inhibitor, and lisaftoclax (APG\u20112575), an orally available BCL\u20112 antagonist\u2014at the American Society of Hematology (ASH) 2025 conference.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=45743#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=45743"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=45743#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0403.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0403.webp","width":1080,"height":608,"caption":"Ascentage Pharma Unveils Promising Results for Olverembatinib and Lisaftoclax at the 67th ASH Annual Meeting"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=45743#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Ascentage Pharma Unveils Promising Results for Olverembatinib and Lisaftoclax at the 67th ASH Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0403.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45743","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=45743"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45743\/revisions"}],"predecessor-version":[{"id":45746,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45743\/revisions\/45746"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/45745"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=45743"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=45743"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=45743"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}